Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
Website:
http://onkuretherapeutics.comNext earnings report:
N/ALast dividends:
N/ANext dividends:
N/APrice
regular market | Thu, 31 Oct 2024 13:30:00 GMTDividend
Analysts recommendations
Institutional Ownership
Included in screeners
OKUR Latest News
OnKure to host a conference call to review key data presented at SABCS and provide a general corporate update on Friday, December 13, 2024 at 8:00 a.m. ET
What type of business is OnKure Therapeutics?
OnKure Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops biologically validated drivers of cancers medicines in the United States. The company's lead product candidate is the OKI-219, a selective inhibitor of PI3Ka harboring the H1047R mutation for the treatment of solid tumors, including breast cancer that is in Phase 1 clinical trial. OnKure Therapeutics, Inc. is headquartered in Boulder, Colorado.
What sector is OnKure Therapeutics in?
OnKure Therapeutics is in the Healthcare sector
What industry is OnKure Therapeutics in?
OnKure Therapeutics is in the Biotechnology industry
What country is OnKure Therapeutics from?
OnKure Therapeutics is headquartered in United States
What is OnKure Therapeutics website?
https://onkuretherapeutics.com
Is OnKure Therapeutics in the S&P 500?
No, OnKure Therapeutics is not included in the S&P 500 index
Is OnKure Therapeutics in the NASDAQ 100?
No, OnKure Therapeutics is not included in the NASDAQ 100 index
Is OnKure Therapeutics in the Dow Jones?
No, OnKure Therapeutics is not included in the Dow Jones index
When was OnKure Therapeutics the previous earnings report?
No data
When does OnKure Therapeutics earnings report?
Next earnings report date is not announced yet